Executive Vice President, Corporate Development & Operations, Chief Legal Officer and Secretary · Kiniksa Pharmaceuticals International, plc (KNSA)

Thomas Beetham

FY2020 is the first fiscal year CompBrief holds for Thomas Beetham as a named executive officer of Kiniksa Pharmaceuticals International; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$2,291,573

Salary $440,000Stock awards $0

2nd of 3 named executive officers at Kiniksa Pharmaceuticals International by FY2020 total.

3 named officers on file for Kiniksa Pharmaceuticals International, FY2020

Thomas Beetham’s pay file — $29

  • 1 fiscal year of pay, line by line
  • KNSA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kiniksa Pharmaceuticals International’s whole pay program stands against its peers

  • Kiniksa Pharmaceuticals International’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KNSA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2021 (DEF 14A).

Free

Get Thomas Beetham’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Thomas Beetham compensation by year

Kiniksa Pharmaceuticals International Summary Compensation Table · the one fiscal year held
In US dollars, as Kiniksa Pharmaceuticals International reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$440,000
Bonus$0
Stock awards$0
Option awards$1,620,173
Non-equity incentive$220,000
Pension and deferred compensation$0
All other$11,400
Total$2,291,573

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 28, 2021, accession 0001104659-21-056540, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kiniksa Pharmaceuticals International, plc filed document, accession 0001104659-21-056540. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
PSU5,855$103,458—
Option8,266—$3.80
Option61,484—$10.36
Option19,687—$30.93
Option23,624—$17.92
Option30,937—$8.83
Option75,000—$15.52
Option75,000—$15.50

Per the Outstanding Equity Awards at Fiscal Year-End table in Kiniksa Pharmaceuticals International, plc's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Kiniksa Pharmaceuticals International’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Sanj PatelChief Executive Officer and Chairman of the Board$5,313,564
Thomas Beetham · this pageExecutive Vice President, Corporate Development & Operations, Chief Legal Officer and Secretary$2,291,573
MBChB. Qasim RizviSenior Vice President, Operations and Chief Commercial Officer$2,252,530

The full Kiniksa Pharmaceuticals International compensation record

free company brief

This page is one person within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kiniksa Pharmaceuticals International proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kiniksa Pharmaceuticals International's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Thomas Beetham's compensation dossier · One-time report. No refunds.